OBJECTIVE: To determine whether persons in a community setting diagnosed with diabetes who received recommended patterns of care experience improved vision outcomes over a 3-year time period. DESIGN: Retrospective, longitudinal, cohort analysis. PARTICIPANTS: Persons diagnosed with diabetes mellitus (DM), with no prior diagnosis of diabetic retinopathy (DR; n = 5989) from the Medicare Current Beneficiary Survey (1992-2004). Persons diagnosed with DM were followed up to 3 years. INTERVENTION: Propensity score matching was used to compare vision outcomes between persons who received guideline-recommended care and those who did not. Receipt of recommended levels of care was defined as receiving each of the following services 0.75 times annually on average: physician examination, ophthalmologist or optometrist examination, hemoglobin A1c level, lipid levels, and urinalysis. MAIN OUTCOME MEASURES: Outcome measures were indicators of DR disease progression: no diagnosed DR to diagnosed background DR, proliferative DR, macular edema, proliferative DR complications, and use of a low-vision aid or blindness. RESULTS: Persons with diagnosed diabetes receiving guideline-recommended care experienced earlier onset of background DR (average treatment effects on the treated [ATT] at 3 years, 0.118; 95% confidence interval [CI], -0.005 to 0.240). There were no differences between those receiving recommended care and others in time to onset of proliferative DR, macular edema, or proliferative DR complications. However, persons who received care consistent with recommendations experienced much lower rates of onset of low vision/blindness than did others (ATT at 3 years, -0.109; 95% CI, -0.189 to -0.030). CONCLUSIONS: Low vision/blindness was substantially reduced over a 3-year period among persons diagnosed with DM who received recommended levels of care.
OBJECTIVE: To determine whether persons in a community setting diagnosed with diabetes who received recommended patterns of care experience improved vision outcomes over a 3-year time period. DESIGN: Retrospective, longitudinal, cohort analysis. PARTICIPANTS: Persons diagnosed with diabetes mellitus (DM), with no prior diagnosis of diabetic retinopathy (DR; n = 5989) from the Medicare Current Beneficiary Survey (1992-2004). Persons diagnosed with DM were followed up to 3 years. INTERVENTION: Propensity score matching was used to compare vision outcomes between persons who received guideline-recommended care and those who did not. Receipt of recommended levels of care was defined as receiving each of the following services 0.75 times annually on average: physician examination, ophthalmologist or optometrist examination, hemoglobin A1c level, lipid levels, and urinalysis. MAIN OUTCOME MEASURES: Outcome measures were indicators of DR disease progression: no diagnosed DR to diagnosed background DR, proliferative DR, macular edema, proliferative DR complications, and use of a low-vision aid or blindness. RESULTS:Persons with diagnosed diabetes receiving guideline-recommended care experienced earlier onset of background DR (average treatment effects on the treated [ATT] at 3 years, 0.118; 95% confidence interval [CI], -0.005 to 0.240). There were no differences between those receiving recommended care and others in time to onset of proliferative DR, macular edema, or proliferative DR complications. However, persons who received care consistent with recommendations experienced much lower rates of onset of low vision/blindness than did others (ATT at 3 years, -0.109; 95% CI, -0.189 to -0.030). CONCLUSIONS:Low vision/blindness was substantially reduced over a 3-year period among persons diagnosed with DM who received recommended levels of care.
Authors: S T Normand; M B Landrum; E Guadagnoli; J Z Ayanian; T J Ryan; P D Cleary; B J McNeil Journal: J Clin Epidemiol Date: 2001-04 Impact factor: 6.437
Authors: Gabriella Tikellis; Shiqi Wang; Nathan Wong; Jie Jin Wang; C Alex Harper; Tien Y Wong Journal: Diabetes Res Clin Pract Date: 2008-01-22 Impact factor: 5.602
Authors: John H Kempen; Benita J O'Colmain; M Cristina Leske; Steven M Haffner; Ronald Klein; Scot E Moss; Hugh R Taylor; Richard F Hamman Journal: Arch Ophthalmol Date: 2004-04
Authors: Cynthia Owsley; Gerald McGwin; David J Lee; Byron L Lam; David S Friedman; Emily W Gower; Julia A Haller; Lisa A Hark; Jinan Saaddine Journal: JAMA Ophthalmol Date: 2015-02 Impact factor: 7.389
Authors: Igor Akushevich; Arseniy P Yashkin; Julia Kravchenko; Fang Fang; Konstantin Arbeev; Frank Sloan; Anatoliy I Yashin Journal: J Diabetes Complications Date: 2018-01-06 Impact factor: 2.852
Authors: Derek LeRoith; Geert Jan Biessels; Susan S Braithwaite; Felipe F Casanueva; Boris Draznin; Jeffrey B Halter; Irl B Hirsch; Marie E McDonnell; Mark E Molitch; M Hassan Murad; Alan J Sinclair Journal: J Clin Endocrinol Metab Date: 2019-05-01 Impact factor: 5.958
Authors: Xinzhi Zhang; Jinan B Saaddine; Chiu-Fang Chou; Mary Frances Cotch; Yiling J Cheng; Linda S Geiss; Edward W Gregg; Ann L Albright; Barbara E K Klein; Ronald Klein Journal: JAMA Date: 2010-08-11 Impact factor: 56.272
Authors: Kathryn Fitch; Thomas Weisman; Tyler Engel; Adam Turpcu; Helen Blumen; Yamina Rajput; Purav Dave Journal: Am Health Drug Benefits Date: 2015-09
Authors: William S Gange; Jennifer Lopez; Benjamin Y Xu; Khristina Lung; Seth A Seabury; Brian C Toy Journal: Diabetes Care Date: 2021-09-02 Impact factor: 19.112